Compare BOSC & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOSC | HOWL |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 30.7M |
| IPO Year | 2002 | 2021 |
| Metric | BOSC | HOWL |
|---|---|---|
| Price | $4.57 | $0.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $8.00 | $5.00 |
| AVG Volume (30 Days) | 53.4K | ★ 482.0K |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.83 | $0.50 |
| 52 Week High | $6.72 | $2.23 |
| Indicator | BOSC | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 42.60 | 30.00 |
| Support Level | $4.43 | N/A |
| Resistance Level | $4.96 | $0.75 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 25.00 | 3.53 |
BOS Better Online Solutions Ltd is a provider of Intelligent Robotics and Supply Chain solutions for enterprises. The company manages its business in three reportable divisions: the Intelligent Robotics segment, the RFID Division segment, and the Supply Chain Solutions segment. The majority of revenue derives from Supply Chain Solutions which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their components-supply needs. Geographically company derives the majority of its revenue from Israel.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.